JP2018052983A5 - - Google Patents

Download PDF

Info

Publication number
JP2018052983A5
JP2018052983A5 JP2017251017A JP2017251017A JP2018052983A5 JP 2018052983 A5 JP2018052983 A5 JP 2018052983A5 JP 2017251017 A JP2017251017 A JP 2017251017A JP 2017251017 A JP2017251017 A JP 2017251017A JP 2018052983 A5 JP2018052983 A5 JP 2018052983A5
Authority
JP
Japan
Prior art keywords
blood
metabolic syndrome
subject
mmol
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017251017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018052983A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018052983A publication Critical patent/JP2018052983A/ja
Publication of JP2018052983A5 publication Critical patent/JP2018052983A5/ja
Pending legal-status Critical Current

Links

JP2017251017A 2009-08-12 2017-12-27 代謝性症候群を予防し又は治療するための方法 Pending JP2018052983A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23327509P 2009-08-12 2009-08-12
US61/233,275 2009-08-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017039099A Division JP6271785B2 (ja) 2009-08-12 2017-03-02 代謝性症候群を予防し又は治療するための方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019073924A Division JP2019104768A (ja) 2009-08-12 2019-04-09 代謝性症候群を予防し又は治療するための方法

Publications (2)

Publication Number Publication Date
JP2018052983A JP2018052983A (ja) 2018-04-05
JP2018052983A5 true JP2018052983A5 (https=) 2018-06-14

Family

ID=43586452

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012524836A Active JP5909182B2 (ja) 2009-08-12 2010-08-11 代謝性症候群を予防し又は治療するための方法
JP2015250186A Pending JP2016041762A (ja) 2009-08-12 2015-12-22 代謝性症候群を予防し又は治療するための方法
JP2017039099A Active JP6271785B2 (ja) 2009-08-12 2017-03-02 代謝性症候群を予防し又は治療するための方法
JP2017251017A Pending JP2018052983A (ja) 2009-08-12 2017-12-27 代謝性症候群を予防し又は治療するための方法
JP2019073924A Pending JP2019104768A (ja) 2009-08-12 2019-04-09 代謝性症候群を予防し又は治療するための方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2012524836A Active JP5909182B2 (ja) 2009-08-12 2010-08-11 代謝性症候群を予防し又は治療するための方法
JP2015250186A Pending JP2016041762A (ja) 2009-08-12 2015-12-22 代謝性症候群を予防し又は治療するための方法
JP2017039099A Active JP6271785B2 (ja) 2009-08-12 2017-03-02 代謝性症候群を予防し又は治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019073924A Pending JP2019104768A (ja) 2009-08-12 2019-04-09 代謝性症候群を予防し又は治療するための方法

Country Status (10)

Country Link
US (4) US20110039766A1 (https=)
EP (4) EP3251686A1 (https=)
JP (5) JP5909182B2 (https=)
CN (3) CN105031605A (https=)
CA (1) CA2770688C (https=)
DK (1) DK2464371T3 (https=)
ES (1) ES2576746T3 (https=)
HK (1) HK1247820A1 (https=)
HU (1) HUE029550T2 (https=)
WO (1) WO2011019809A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2964555T3 (es) 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
WO2011044044A1 (en) * 2009-10-05 2011-04-14 Cornell University Methods for the prevention or treatment of heart failure
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CN104271146A (zh) * 2012-03-30 2015-01-07 康肽德生物医药技术有限公司 用于预防和治疗神经病的方法和组合物
JP2015529655A (ja) 2012-08-02 2015-10-08 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
AU2013334788A1 (en) * 2012-10-22 2015-06-04 Henry Ford Health Systems Methods for reducing risks associated with heart failure and factors associated therewith
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法
US9687519B2 (en) 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
ES2755134T3 (es) * 2013-03-01 2020-04-21 Stealth Biotherapeutics Corp Métodos para el tratamiento de enfermedad mitocondrial
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2925475A1 (en) * 2013-09-27 2015-04-02 Cornell University Use of aromatic-cationic peptides to treat cholesterol-induced mitochondrial dysfunction
JP2016540762A (ja) * 2013-12-02 2016-12-28 ステルス バイオセラピューティックス コープ 白斑の治療のための組成物及び方法
WO2017066659A1 (en) * 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Jag1 expression predicts therapeutic response in nash
WO2017180535A1 (en) * 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
CN108210900A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肥胖症的药物及其用途
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
WO2018107686A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种治疗动脉粥样硬化及其并发症的方法
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
JP7171671B2 (ja) * 2020-10-22 2022-11-15 野村マイクロ・サイエンス株式会社 超純水製造システム及び超純水製造方法
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SG64368A1 (en) * 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5468798A (en) * 1994-02-18 1995-11-21 Whitford Corporation Basecoat for a coating system
ATE255450T1 (de) * 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
WO1999055321A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
DE60042338D1 (de) * 1999-10-04 2009-07-16 Univ New Jersey Med TAR RNA bindende Peptide
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
US7498297B2 (en) * 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
EP1599216B9 (en) * 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
PL2604286T3 (pl) * 2003-05-01 2015-03-31 Cornell Res Foundation Inc Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
US20070110728A1 (en) * 2003-11-28 2007-05-17 Develogen Aktiengesellschaft Method for preventing and treating diabetes using dg119
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP1734963A4 (en) * 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CN104788540B (zh) * 2005-09-16 2019-10-18 科内尔研究基金会 用于减少cd36表达的方法
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
EP3741381B1 (en) * 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
WO2011044044A1 (en) * 2009-10-05 2011-04-14 Cornell University Methods for the prevention or treatment of heart failure

Similar Documents

Publication Publication Date Title
JP2018052983A5 (https=)
JP2013501802A5 (https=)
JP2022009125A5 (https=)
JP2012520866A5 (https=)
JP2013533858A5 (https=)
JP2007500236A5 (https=)
JP2012517478A5 (https=)
CA2513567A1 (en) Cop 1 for treatment of inflammatory bowel diseases
JP2013541583A5 (https=)
JP2013518124A5 (https=)
JP2003519228A5 (https=)
JP2002528502A5 (https=)
JP2017514911A5 (https=)
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
MX2007015085A (es) Tratamiento de enfermedades del higado en donde el hierro juega un papel importante en patogenesis.
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
JP2024504555A (ja) 急性膵炎を予防及び治療するための薬物の製造におけるノルハルマンの使用
JP2012525358A5 (https=)
JP2023531675A5 (https=)
JP2011527317A5 (https=)
JP2021535163A5 (https=)
JP2023523247A (ja) ウイルス感染症の治療のためのレニン－アンジオテンシン系（ｒａｓ）モジュレーター、それを含む医薬組成物、およびそれを用いた治療方法
JP2023531930A5 (https=)
RU2013120345A (ru) Новые способы лечения инфекции, вызванной вирусом гепатита с
Kamal et al. 585 Peginterferon alpha-2b therapy with and without ribavirin in patients with thalassemia: A randomized study